Lepton and the Medical Center University of Freiburg sign a Sponsored Research Agreement to use miRNA Castling Technology to improve CAR T cells persistence and cytotoxicity for treatment of Cancer

Lepton Pharmaceuticals announces that it signed a sponsored research agreement with the Institute for Transfusion Medicine and Gene Therapy (ITG), Medical Center – University of Freiburg, Germany, with the purpose of applying its proprietary miRNA Castling Technology to improve T- cells and CAR T cells persistence and cytotoxicity in the context of different types of human cancers.  The research is led by Dr. Claudio Mussolino, PhD, Group Leader – Genome and Epigenome Engineering of the Institute.

The institute’s research efforts focus on the development and evaluation of safe platforms for the manufacturing of advanced therapy medicinal products using gene editing technologies. It offers valuable combination of an established facility for the GMP-compliant production of hemotherapies with specialized scientists in developing advanced therapies, thus in ideal position to develop new perspectives in cell and gene therapy.